Education BS. in Seoul National University School of Pharmacy MS in Harvard School of Public Health Ph.D in Ulsan University, College of Medicine Professional Experience (present) Vice Chief, Convergence AI Institute for Drug Discovery (present) Adjunct Professor, Seoul National University, Graduate School of Convergence Science and Technology (former) Data Scientist, Roche (former) Researcher, Tufts Medical Center

Education 2022 Dr. rer. nat. (summa cum laude), Max-Planck Institute for Multidisciplinary Sciences, University of Göttingen, Göttingen, Germany 2016 M.Sc. in Computer Science, LMU, Munich, Germany 2014 B.Sc. in Bioinformatics, LMU & TUM, Munich, Germany Until 2010 Abitur, Schönbuch Gymnasium, Holzgerlingen, Germany Professional Experience 2022-present Postdoctoral fellow, Seoul National University 2022 Researcher, Max-Planck Institute for Biophysical Chemistry 2017-2022 PhD candidate, Max-Planck Institute for Biophysical Chemistry 2014-2017 Research assistant, Max-Planck Institute for Biophysical Chemistry Gene Center, Ludwig Maximilian University 2011-2012 Research assistant, Technical University of Munich

Education 2022 Ph.D., KAIST, Department of Chemical and Biomolecular Engineering 2018 M.S., KAIST, Graduate School of EEWS 2016 B.S., KAIST, Department of Chemical and Biomolecular Engineering Professional Experience 2022-present Senior Researcher, Korea Research Institute of Chemical Technology, Data Convergence Drug Research Center

Academic Career 2015 PhD in Veterinary Pathology, Jeonbuk National University 2002 MS in Veterinary Pathology, Jeonbuk National University 2000 BS in Veterinary Medicine, Jeonbuk National University Professional Experience 2002-present Senior Researcher/Toxicologic Pathologist, Korea Institute of Toxicology (KIT) 2020-present Principal Researcher, Smart AI Lab for Toxicity Assessment, Korea Institute of Toxicology(KIT)

Dr. Manavalan earned his Ph.D. in Computational Biology from Ajou University in 2011. His professional journey includes a research fellowship at the Korea Institute for Advanced Study (KIAS) from 2011 to 2017, followed by research positions at Ajou University Medical School until 2022. Since joining SKKU in early 2022, Dr. Balachandran Manavalan is an Associate Professor at the Department of Integrative Biotechnology, Sungkyunkwan University (SKKU), where he leads the Computational Biology and Bioinformatics Laboratory. His research interests are bioinformatics, data mining, and machine learning, with a strong focus on developing advanced computational and artificial intelligence (AI) methodologies, particularly deep learning and ensemble learning strategies. His work is focused on developing robust and high-precision AI-driven predictive models for a wide array of biological and biomedical challenges. He has introduced several novel computational frameworks, including feature representation learning, itereative feature representation learning, and adaptive learning. These frameworks have been widely applied in different research fields. Manavalan has consistently contributed cutting-edge solutions to pressing challenges in biotechnology and computational life sciences, with his prolific publication record in high-impact journals (over 130 research papers) underscoring the significant influence of his work. He has been listed as the top 2% highly cited researcher in the field of Bioinformatics from 2020 to now. Based on the high-quality publication, he has been ranked 6th in peptide and 18th in Bioinformatics, according to ScholarGPS. Also, he has been ranked 6th in Dr. Manavalan is also noted for integrating multi-modal deep learning frameworks that combine molecular sequences, structures, and images, enhancing both model accuracy and interpretability, with a strong emphasis on Explainable AI (XAI). His commitment to open science is evident through the regular release of source codes and web-based tools, fostering broader scientific utility. Academically, Dr. Manavalan earned his Ph.D. in Computational Biology from Ajou University in 2011. His professional journey includes a research fellowship at the Korea Institute for Advanced Study (KIAS) from 2011 to 2017, followed by research positions at Ajou University Medical School until 2022. Since joining SKKU in early 2022, Professor Manavalan has consistently contributed cutting-edge solutions to pressing challenges in biotechnology and computational life sciences, with his prolific publication record in high-impact journals underscoring the significant influence of his work.

Education 2009 Ph.D. Chemistry, POSTECH, Pohang, Korea 2004 B.S. Chemistry and Physics, POSTECH, Pohang, Korea Professional Experience 2011-present Assist./Assoc./Full Professor, Department of Chemistry, KAIST, Daejeon, Korea 2020-present CEO and Co-Founder, HITS Inc., Seoul, Korea 2024 Vice Director, Convergence AI Institute for Drug Discovery, Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Seoul, Korea 2022-2024 Director, Korea AI Center for Drug Discovery and Development, Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Seoul, Korea 2010 Postdoctoral Fellow, Max-Planck Institute of Microstructure Physics, Halle, Germany 2009 Postdoctoral Fellow, Department of Chemistry, POSTECH, Pohang, Korea

Education 1995-2000 Ph. D., Cancer Research Institute, Kanazawa University, Japan 1993-1995 MS, Department of Molecular Biology, Pusan National University, Korea 1985 –1989 BS, Department of Molecular Biology, Pusan National University, Korea Professional Experience 2023-present Director, Therapeutics & biotechnology division, Korea Research Institute of Chemical Technology, Korea 2008-present Principal Scientist, Medicinal Science Division, Korea Research Institute of Chemical Technology, Korea 2002-2007 Senior Scientist, Medicinal Science Division, Korea Research Institute of Chemical Technology, Korea 2000-2002 Postdoctoral fellow, Department of Pharmacology, Seoul National University, Korea 2000 Visiting scientist, Virus institute, Kyoto University, Japan

Dr. Kim is an expert in the evaluation of drug safety and efficacy, with over 27 years of experience at the Ministry of Food and Drug Safety (MFDS) of Korea. She currently serves as the director of the division of Cardiovascular and Neurological Products. Leveraging her deep expertise in drug review, she has led the development of various regulatory guidelines, proactively guiding the pharmaceutical industry in setting development directions and establishing a scientific framework for drug assessment. She has also been actively involved in a wide range of regulatory activities, including participation in ICH Expert Working Groups(EWGs). In particular, as emerging technologies such as pharmacometrics, pharmacogenomics, and artificial intelligence(AI) are increasingly applied in drug development, Dr. Kim has played a key role in providing regulatory guidance to support their integration into the pharmaceutical field.

After graduating from the Department of Public Administration at Korea University (Bachelor's degree) and George Washington University with a major in Economics (Master's degree), I entered the Ministry of Science and Technology (currently the Ministry of Science and ICT) as a civil servant in 2007 after passing the 50th Administrative Examination. Throughout my career, I have been responsible for various tasks such as personal basic research support, overall management of basic research R&D, and formulation of science and technology policies. After being promoted to a director, I served as the head of the finance team and the personnel team. In January 2024, I assumed the position of Director of Bioscience Technology Division, where I am responsible for fostering advanced fields in bioscience such as synthetic biology and supporting overseas expansion of bio-venture companies. (The Division name has been changed to Advanced Biotechnology Division due to organizational restructuring on May 27th.)

Education 1996-2000 B.Sc. in Biochemistry, Dongguk University 2000-2002 M.S. in Pharmacy, Pusan National University 2002- 2006 Ph.D. in Pharmacy, Pusan National University Professional Experience 2009-현재 Principal Research Scientist, Korea Institute of Toxicology 2009-2020 Associate professor (adjunt), Toxicology, University of Sicence and Technology (UST) 2006-2009 Postdoctoral fellow, NIH/NCI, USA

Education 2005 Ph.D., Molecular and Human Genetics, Baylor College of Medicine 2001 M.S., Molecular Biology, Korea University 1999 B.S., Food Science and Biotechnology, Korea University Professional Experience 2023–Present Adjunct Professor, Korea University (Sejong) 2022–Present Associate Professor, Chungnam National University (Daejeon) 2018–Present CEO, Calici Therapeutics Inc. (USA)